Poolbeg Pharma is a clinical-stage pharmaceutical company focused on the development and commercialisation of therapies to treat and prevent infectious diseases. Headquartered in London, the business is a spin out from Open Orphan plc and the management team has proven capabilities in identifying, acquiring and accelerating assets through development to commercialisation. It has adopted a capital-light model which enables it to develop multiple products faster and more cost effectively than the traditional biotech model, and the company aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation.
The company’s lead asset is POLB 001, a drug with the potential to treat serious unmet needs in patients suffering from severe influenza.